Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)
Objectives. Overactive bladder (OAB) is a chronic disease, but comparative trials of anticholinergics, which are commonly used for treatment of OAB, have generally been performed for up to 12 weeks only. There is no comparative study of a long-term intervention. Methods. We conducted a 52-week prosp...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2011/854697 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567630432567296 |
|---|---|
| author | Masayoshi Zaitsu Koji Mikami Noriko Ishida Takumi Takeuchi |
| author_facet | Masayoshi Zaitsu Koji Mikami Noriko Ishida Takumi Takeuchi |
| author_sort | Masayoshi Zaitsu |
| collection | DOAJ |
| description | Objectives. Overactive bladder (OAB) is a chronic disease, but comparative trials of anticholinergics, which are commonly used for treatment of OAB, have generally been performed for up to 12 weeks only. There is no comparative study of a long-term intervention. Methods. We conducted a 52-week prospective randomized comparative study to evaluate the efficacy and tolerability of two anticholinergics. Results. Forty-one Japanese patients with untreated OAB were randomly assigned to imidafenacin and solifenacin groups. There was no difference in OABSS and KHQ scores between the two groups, but the severity and incidence of adverse events caused by the anticholinergics showed increased differences between the groups with time. The severity of dry mouth and the incidence of constipation were significantly lower in the imidafenacin group (𝑃=0.0092 and 𝑃=0.0013, resp.). Conclusions. This study is the first long-term trial to show differences in the properties of anticholinergics that were not detected in short-term studies. Since OAB is a chronic disease, we conclude that imidafenacin is preferable to solifenacin from a perspective of safety. |
| format | Article |
| id | doaj-art-026fbd0c06b146f3bb009799386bbcd3 |
| institution | Kabale University |
| issn | 1687-6369 1687-6377 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Urology |
| spelling | doaj-art-026fbd0c06b146f3bb009799386bbcd32025-02-03T01:00:54ZengWileyAdvances in Urology1687-63691687-63772011-01-01201110.1155/2011/854697854697Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)Masayoshi Zaitsu0Koji Mikami1Noriko Ishida2Takumi Takeuchi3Department of Urology, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki 211-8510, JapanDepartment of Urology, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki 211-8510, JapanDepartment of Pharmacy, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki 211-8510, JapanDepartment of Urology, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki 211-8510, JapanObjectives. Overactive bladder (OAB) is a chronic disease, but comparative trials of anticholinergics, which are commonly used for treatment of OAB, have generally been performed for up to 12 weeks only. There is no comparative study of a long-term intervention. Methods. We conducted a 52-week prospective randomized comparative study to evaluate the efficacy and tolerability of two anticholinergics. Results. Forty-one Japanese patients with untreated OAB were randomly assigned to imidafenacin and solifenacin groups. There was no difference in OABSS and KHQ scores between the two groups, but the severity and incidence of adverse events caused by the anticholinergics showed increased differences between the groups with time. The severity of dry mouth and the incidence of constipation were significantly lower in the imidafenacin group (𝑃=0.0092 and 𝑃=0.0013, resp.). Conclusions. This study is the first long-term trial to show differences in the properties of anticholinergics that were not detected in short-term studies. Since OAB is a chronic disease, we conclude that imidafenacin is preferable to solifenacin from a perspective of safety.http://dx.doi.org/10.1155/2011/854697 |
| spellingShingle | Masayoshi Zaitsu Koji Mikami Noriko Ishida Takumi Takeuchi Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study) Advances in Urology |
| title | Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study) |
| title_full | Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study) |
| title_fullStr | Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study) |
| title_full_unstemmed | Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study) |
| title_short | Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study) |
| title_sort | comparative evaluation of the safety and efficacy of long term use of imidafenacin and solifenacin in patients with overactive bladder a prospective open randomized parallel group trial the list study |
| url | http://dx.doi.org/10.1155/2011/854697 |
| work_keys_str_mv | AT masayoshizaitsu comparativeevaluationofthesafetyandefficacyoflongtermuseofimidafenacinandsolifenacininpatientswithoveractivebladderaprospectiveopenrandomizedparallelgrouptrialtheliststudy AT kojimikami comparativeevaluationofthesafetyandefficacyoflongtermuseofimidafenacinandsolifenacininpatientswithoveractivebladderaprospectiveopenrandomizedparallelgrouptrialtheliststudy AT norikoishida comparativeevaluationofthesafetyandefficacyoflongtermuseofimidafenacinandsolifenacininpatientswithoveractivebladderaprospectiveopenrandomizedparallelgrouptrialtheliststudy AT takumitakeuchi comparativeevaluationofthesafetyandefficacyoflongtermuseofimidafenacinandsolifenacininpatientswithoveractivebladderaprospectiveopenrandomizedparallelgrouptrialtheliststudy |